Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2020; 74(1): 11–17. doi:10.14735/amgh202011.

Guidelines of the Slovak Working Group on IBD in SGS for the Treatment of IBD at Reproductive Age

Zuzana Zelinková1, Jozef Baláž2, Ivan Bunganič3, Iveta Čierna4, Laura Gombošová5, Miloš Greguš6,7, Tibor Hlavatý8, Milan Hlista9, Martin Huorka10, Barbora Kadlečková1, Tomáš Koller10, Peter Lietava11, Branislav Valach12, Jozef Záň13, Mária Zakuciová14

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Bátovský M, Jurgoš Ľ, Bielik J. Racionálna liečba chronických zápalov čreva. Metodický list racionálnej farmakoterapie 2002; 6(7): 1–4.
2. Greguš M, Huorka M, Lukáč Ľ. Racionálna liečba chronických nešpecifických zápalov čreva. Metodický list racionálnej farmakoterapie 2007; 5–6(11): 1–8.
3. Kužela L, Zakuciová M. Racionálna liečba chronických nešpecifických zápalov čreva. Metodický list racionálnej farmakoterapie a liekovej politiky MZSR 2012; 7A–B.
4. Hlavatý T, Krajčovičová A, Zakuciova M et al. Odporúčania Pracovnej skupiny pre IBD Slovenskej gastroenterologickej spoločnosti pre liečbu ulceróznej kolitídy. Gastroent Hepatol 2017; 71(3): 229–240. doi:10.14735/amgh2017csgh.info05.
5. Greguš M, Hlavatý T, Krajčovičová A et al. Odporúčania PS-IBD SGS – optimalizácia biologickej liečby pri strate odpovede po indukcii a počas udržiavacej fázy liečby. Gastroent Hepatol 2018; 72(5): 426–431. doi:10.14735/amgh2018426.
6. Koller T, Tóth J, Hlavatý T et al. Odporúčania Pracovnej skupiny pre IBD Slovenskej gastroenterologickej spoločnosti pre liečbu Crohnovej choroby. Gastroent Hepatol 2018; 72(1): 27–40. doi:10.14735/amgh201827.
7. Brown BB. Delphi process: a methodology used for the elicitation of opinions of experts. Santa Monica, California: Rand Corporation; 1968.
8. Calvet X, Panés J, Alfaro N et al. Delphi consensus statement: quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis 2014; 8(3): 240–251. doi: 10.1016/j.crohns.2013.10.010.
9. Cornish J, Tan E, Teare J et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56(6): 830–837. doi: 10.1136/gut.2006.108324.
10. Levi AJ, Fisher AM, Hughes L et al. Male infertility due to sulphasalazine. Lancet 1979; 2(8137): 276–278. doi: 10.1016/s0140-6736(79)90292-7.
11. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979; 31(5): 538–540. doi: 10.1016/s0015-0282(16)44000-8.
12. Birnie GG, Mc Leod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22(6): 452–455. doi: 10.1136/gut.22.6.452.
13. O’Moráin C, Smethurst P, Doré CJ et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25(10): 1078–1084. doi: 10.1136/gut.25.10.1078.
14. Riley SA, Lecarpentier J, Mani V et al. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut 1987; 28(8): 1008–1012. doi: 10.1136/gut.28.8.1008.
15. Di Paolo MC, Paoluzi OA, Pica R et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Dig Liver Dis 2001; 33(7): 563–569. doi: 10.1016/s1590-8658(01)80108-0.
16. Chermesh I, Eliakim R. Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 2004; 36(8): 551–552. doi: 10.1016/j.dld.2003.11.030.
17. Shin T, Kobori Y, Suzuki K et al. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. Syst Biol Reprod Med 2014; 60(6): 373–376. doi: 10.3109/19396368.2014.952391.
18. Dejaco C, Mittermaier C, Reinisch W et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001; 121(5): 1048–1053. doi: 10.1053/gast.2001.28692.
19. Rajapakse RO, Korelitz BI, Zlatanic J et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000; 95(3): 684–688. doi: 10.1111/j.1572-0241.2000.01846.x.
20. Francella A, Dyan A, Bodian C et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124(1): 9–17. doi: 10.1053/gast.2003.50014.
21. Nørgård B, Pedersen L, Jacobsen J et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004; 19(6): 679–685. doi: 10.1111/j.1365-2036.2004.01889.x.
22. Teruel C, López-San Román A, Bermejo F et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010; 105(9): 2003–2008. doi: 10.1038/ajg.2010.138.
23. Akbari M, Shah S, Velayos FS et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(1): 15–22. doi: 10.1002/ibd.22948.
24. Grosen A, Nersting J, Bungum M et al. Sperm DNA integrity is unaffected by thiopurine treatment in men with inflammatory bowel disease. J Crohns Colitis 2019; 13(1): 3–11. doi: 10.1093/ecco-jcc/jjy086.
25. van der Woude CJ, Ardizzone S, Bengtson MB et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9(2): 107–124. doi: 10.1093/ecco-jcc/jju006.
26. Sands K, Jansen R, Zaslau S et al. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 2015; 41(9): 821–834. doi: 10.1111/apt.13142.
27. Narendranathan M, Sandler RS, Suchindran CM et al. Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989; 11(4): 403–406. doi: 10.1097/00004836-198908000-00011.
28. Mahadevan U, Dubinsky MC, Su C et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis 2018; 24(12): 2494–2500. doi: 10.1093/ibd/izy160.
29. Villiger PM, Caliezi G, Cottin V et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010; 69(10): 1842–1844. doi: 10.1136/ard.2009.127423.
30. Katz JA, Antoni C, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99(12): 2385–2392. doi: 10.1111/j.1572-0241.2004.30186.x.
31. Mahadevan U, Terdiman JP, Aron J et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis 2005; 11(4): 395–399. doi: 10.1097/01.mib.0000164023.10848.c4.
32. Zelinkova Z, van der Ent C, Kuipers EJ et al. Su1148 Effect of Adalimumab on Semen Quality in Inflammatory Bowel Disease Patients. Gastroenterology 2013; 144: S411.
33. Mahadevan U, Vermeire S, Lasch K et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45(7): 941–950. doi: 10.1111/apt.13960.
34. Woolfson K, Cohen Z, McLeod RS. Crohn’s disease and pregnancy. Dis Colon Rectum 1990; 33(10): 869–873. doi: 10.1007/bf02051924.
35. Korelitz BI. Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am 1998; 27(1): 213–224. doi: 10.1016/s0889-8553(05)70354-x.
36. Beniada A, Benoist G, Maurel J et al. Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature. J Gynecol Obstet Biol Reprod (Paris) 2005; 34(6): 581–588. doi: 10.1016/s0368-2315(05)82883-2.
37. Bengtson MB, Solberg IC, Aamodt G et al. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm Bowel Dis 2010; 16(5): 847–855. doi: 10.1002/ibd.21120.
38. Bortoli A, Pedersen N, Duricova D et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003–2006. Aliment Pharmacol Ther 2011; 34(7): 724–734. doi: 10.1111/j.1365-2036.2011.04794.x.
39. Oron G, Yogev Y, Shcolnick S et al. Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain. J Matern Fetal Neonatal Med 2012; 25(11): 2256–2260. doi: 10.3109/14767058.2012.684176.
40. Bröms G, Granath F, Linder M et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol 2012; 10(11): 1246–1252. doi: 10.1016/j.cgh.2012.08.018.
41. Leung YP, Kaplan GG, Coward S et al. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis 2015; 9(9): 223–230. doi: 10.1093/ecco-jcc/jjv006.
42. de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol 2016; 111(9): 1305–1312. doi: 10.1038/ajg.2016.254.
43. de Lima A, Zelinkova Z, Mulders AG et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 2016; 14(9): 1285–1292. doi: 10.1016/j.cgh.2016.03.018.
44. Mogadam M, Dobbins WO 3rd, Korelitz BI et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80(1): 72–76.
45. Nørgård B, Czeizel AE, Rockenbauer M et al. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 2001; 15(4): 483–486. doi: 10.1046/j.1365-2036.2001.00962.x.
46. Nørgård B, Fonager K, Pedersen L et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003; 52(2): 243–247. doi: 10.1136/gut.52.2.243.
47. Rahimi R, Nikfar S, Rezaie A et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25(2): 271–275. doi: 10.1016/j.reprotox.2007.11.010.
48. Källén B. Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring. Scand J Gastroenterol 2014; 49(4): 442–448. doi: 10.3109/00365521.2013.879734.
49. Jharap B, de Boer NK, Stokkers P et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014; 63(3): 451–457. doi: 10.1136/gutjnl-2012-303615.
50. Angelberger S, Reinisch W, Messerschmidt A et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis 2011; 5(2): 95–100. doi: 10.1016/j.crohns.2010.10.005.
51. Coelho J, Beaugerie L, Colombel JF et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60(2): 198–203. doi: 10.1136/gut.2010.222893.
52. Shim L, Eslick GD, Simring AA et al. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011; 5(3): 234–238. doi: 10.1016/j.crohns.2011.01.009.
 
53. Casanova MJ, Chaparro M, Domènech E et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108(3): 433–440. doi: 10.1038/ajg.2012.430.
54. Kanis SL, de Lima-Karagiannis A, de Boer NK et al. Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. Clin Gastroenterol Hepatol 2017; 15(8): 1232–1241. doi: 10.1016/j.cgh.2017.02.041.
55. Hutson JR, Matlow JN, Moretti ME et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013; 33: 1–8.
56. de Meij TG, Jharap B, Kneepkens CM et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38(1): 38–43. doi: 10.1111/apt.12334.
57. Kozlowski RD, Steinbrunner JV, MacKenzie AH et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88(6): 589–592. doi: 10.1016/0002-9343(90)90522-f.
58. Schnitzler F, Fidder H, Ferrante M et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17(9): 1846–1854. doi: 10.1002/ibd.21583.
59. Mahadevan U, Martin CF, Sandler RS et al. 865 PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012; 142: S149.
60. Bortlik M, Machkova N, Duricova D et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF- α therapy during pregnancy: three-center study. Scand J Gastroenterol 2013; 48(8): 951–958. doi: 10.3109/00365521.2013.812141.
61. Bröms G, Granath F, Ekbom A et al. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol 2016; 14(2): 234–241. doi: 10.1016/j.cgh.2015.08.039.
62. de Lima A, Zelinkova Z, van der Ent C et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut 2016; 65(8): 1261–1368. doi: 10.1136/gutjnl-2015-309321.
63. Chaparro M, Verreth A, Lobaton T et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol 2018; 113(3): 396–403. doi: 10.1038/ajg.2017.501.
64. Luu M, Benzenine E, Doret M et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol 2018; 113(11): 1669–1677. doi: 10.1038/s41395-018-0176-7.
65. Roy A, Chambers CD, Martin C et al. Exposure to biologic therapy and childhood development among offspring of women with inflammatory bowel disease: results from the piano registry. Gastroenterology 2017; 152: S85–S86.
66. Kattah MG, Milush JM, Burt T et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol 2018; 9(4): 143. doi: 10.1038/s41424-018-0018-3.
67. Duricova D, Dvorakova E, Hradsky O et al. Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis 2019; 25(4): 789–796. doi: 10.1093/ibd/izy294.
68. Beaulieu DB, Ananthakrishnan AN, Martin C et al. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol 2018; 16(1): 99–105. doi: 10.1016/j.cgh.2017.08.041.
69. de Lima A, Kanis SL, Escher JC et al. Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero. J Crohns Colitis 2018; 12(8): 948–953. doi: 10.1093/ecco-jcc/jjy053.
70. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104(1): 228–233. doi: 10.1038/ajg.2008.71.
71. Zelinkova Z, de Haar C, de Ridder L et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33(9): 1053–1058. doi: 10.1111/j.1365-2036.2011.04617.x.
72. Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11(3): 286–292. doi: 10.1016/j.cgh.2012.11.011.
73. Mahadevan U, Kane SV, Church JA et al. 499 the effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008; 134: A69.
74. Zelinkova Z, van der Ent C, Bruin KF et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11(3): 318–321. doi: 10.1016/j.cgh.2012.10.024.
75. Seow CH, Leung Y, Vande Casteele N et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45(10): 1329–1338. doi: 10.1111/apt.14040.
76. Kanis SL, de Lima-Karagiannis A, van der Ent C et al. Anti-TNF levels in cord blood at birth are associated with anti-TNF type. J Crohns Colitis 2018; 12(8): 939–947. doi: 10.1093/ecco-jcc/jjy058.
77. Ebrahimi N, Herbstritt S, Gold R et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21(2): 198–205. doi: 10.1177/1352458514546790.
78. Zelinkova Z, Berakova K, Podmanicky D et al. Placental MadCAM1 expression and potential consequences for the treatment with vedolizumab during pregnancy. Gastroenterology 2017; 152: S764–S765.
79. Moens A, van Hoeve K, Humblet E et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis 2019; 13(1): 12–18. doi: 10.1093/ecco-jcc/jjy142.
80. Schneider H, Weber CE, Hellwig K et al. Natalizumab treatment during pregnancy – effects on the neonatal immune system. Acta Neurol Scand 2013; 127(1): e1–4. doi: 10.1111/ane.12004.
81. Bar-Gil Shitrit A, Ben Ya’acov A, Livovsky DM et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol 2019; 114(7): 1172–1175. doi: 10.14309/ajg.0000000000000186.
82. Venturin C, Nancey S, Danion P et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol 2017; 17(1): 80. doi: 10.1186/s12876-017-0633-6.
83. Matro R, Martin CF, Wolf D et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 2018; 155(3): 696–704. doi: 10.1053/j.gastro.2018.05.040.
84. Rowan CR, Cullen G, Mulcahy HE et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis 2018; 12(3): 376–378. doi: 10.1093/ecco-jcc/jjx141.
85. Klenske E, Osaba L, Nagore D et al. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease. J Crohns Colitis 2019; 13(2): 267–269. doi: 10.1093/ecco-jcc/jjy153.
86. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183(7): 796–804. doi: 10.1503/cmaj.101063.
87. Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn’s disease and adrenal suppression in her newborn. Neonatology 2008; 94(4): 306–309. doi: 10.1159/000151652.
88. Beaulieu DB, Ananthakrishnan AN, Issa M et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis 2009; 15(1): 25–28. doi: 10.1002/ibd.20640.
89. Aratari A, Margagnoni G, Koch M et al. Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis. Journal of Crohns Colitis 2011; 5(3): 262. doi: 10.1016/j.crohns.2011.02.004.
90. Bar Oz B, Hackman R, Einarson T et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71(8): 1051–1055. 10.1097/00007890-200104270-00006.
91. Branche J, Cortot A, Bourreille A et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009; 15(7): 1044–1048. doi: 10.1002/ibd.20858.
92. Koss CA, Baras DC, Lane SD et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother 2012; 56(9): 4800–4805. doi: 10.1128/AAC.06477-11.
93. Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 1995; 28(1): 59–64. doi: 10.1006/faat.1995.1146.
94. Berkovitch M, Pastuszak A, Gazarian M et al. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 84(4): 535–538.
95. Hatch Q, Champagne BJ, Maykel JA et al. Crohn’s disease and pregnancy: the impact of perianal disease on delivery methods and complications. Dis Colon Rectum 2014; 57(2): 174–178. doi: 10.1097/DCR.0b013e3182a41381.
96. Ramalingam T, Box B, Mortensen NM. Pregnancy delivery and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2003; 46(9): 1292. doi: 10.1007/s10350-004-6730-y.
97. Hahnloser D, Pemberton JH, Wolff BG et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. Dis Colon Rectum 2004; 47(7): 1127–1135. doi: 10.1007/s10350-004-0569-0.
98. Remzi FH, Gorgun E, Bast J et al. Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. Dis Colon Rectum 2005; 48(9): 1691–1699. doi: 10.1007/s10350-005-0124-7.
99. Polle SW, Vlug MS, Slors JF et al. Effect of vaginal delivery on long-term pouch function. Br J Surg 2006; 93(11): 1394–1401. doi: 10.1002/bjs.5467.
100. Esbjörner E, Järnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1987; 76(1): 137–142. doi: 10.1111/j.1651-2227.1987.tb10430.x.
101. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993; 105(4): 1057–1060. doi: 10.1016/0016-5085(93)90949-d.
102. Diav-Citrin O, Park YH, Veerasuntharam G et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114(1): 23–28. doi: 10.1016/s0016-5085(98)70628-6.
103. Marteau P, Tennenbaum R, Elefant E et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998; 12(11): 1101–1108. doi: 10.1046/j.1365-2036.1998.00417.x.
104. Gardiner SJ, Gearry RB, Roberts RL et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 2006; 62(4): 453–456. 10.1111/j.1365-2125.2006.02639.x.
105. Christensen LA, Dahlerup JF, Nielsen MJ et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28(10): 1209–1213. doi: 10.1111/j.1365-2036.2008.03843.x.
106. Zelinkova Z, De Boer IP, Van Dijke MJ et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2009; 30(1): 90–91. doi: 10.1111/j.1365-2036.2009.03996.x.
107. Moretti ME, Sgro M, Johnson DW et al. Cyclosporine excretion into breast milk. Transplantation 2003; 75(12): 2144–2146. doi: 10.1097/01.TP.0000066352.86763.D0.
108. Beitins IZ, Bayard F, Ances IG et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81(5): 936–945. doi: 10.1016/s0022-3476(72)80547-x.
109. Ost L, Wettrell G, Björkhem I et al. Prednisolone excretion in human milk. J Pediatr 1985; 106(6): 1008–1011. doi: 10.1016/s0022-3476(85)80259-6.
110. Ben-Horin S, Yavzori M, Katz L et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8(5): 475–476. doi: 10.1016/j.cgh.2009.11.023.
111. Ben-Horin S, Yavzori M, Kopylov U et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011; 5(6): 555–558. doi: 10.1016/j.crohns.2011.05.006.
112. Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mothers and infants. J Perinat Med 1983; 11(2): 114–120. doi: 10.1515/jpme.1983.11.2.114.
113. Gardner DK, Gabbe SG, Harter C. Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant. Clin Pharm 1992; 11(4): 352–354.

Kreditovaný autodidaktický test